Introduction
Nervous system involvement in systemic lupus erythematosus (SLE) may present with diverse neurological or psychiatric symptomatology and may involve both central and peripheral dysfunction. Presentations may include stroke syndrome, seizures, psychoses, dementia, organic brain syndromes, chorea, coma as well as transverse myelopathy, peripheral neuropathy, myositis and a variety of syndromes affecting the optic nerves. Estimations of the prevalence of neuropsychiatric (NP) SLE vary from 14% to 75% reflecting variable diagnostic methodologies and criteria.`9
In addition to these major clinical syndromes, patients with SLE may often be subject to 'soft' neurological and/or psychiatric problems, for example, parasthaesias, migraine-type headaches, anxiety states, mood swings, and cognitive problems such as difficulty in concentration, memory and word finding.
A few of the above symptomatologies may antedate the appearance of definitive, diagnosable SLE by months, or even years. An example of this is epilepsy, an isolated phenomenon which has been noted in childhood or early teens, only to be followed many years later by SLE.'0 Chorea is another example of such a manifestation." It has recently become clear that many of the focal manifestations of NP-SLE such as transient ischaemic attacks (TIAs) or strokes may occur on the basis of vascular occlusions associated with anti-phospholipid antibodies (aPL).2-'5 Epilepsy itself, as the sole manifestation of such vascular occlusions has also been associated with aPL.'6",7 However, organic brain syndromes'8 and multiinfarct dementias'9'20 are examples of diffuse, nonfocal conditions also associated with this group of antibodies, so an attempted distinction into focal and diffuse is not as clear as originally conceived with regard to the clinical presentations associated with the aPL coagulopathy.
Neurological (or psychiatric) problems in lupus patients and their therapy confront the neurologist and rheumatologist with major therapeutic dilemmas. Should the patient receive 'pulse' steroids or cytotoxics and should these be combined with anticoagulant therapy if the aPL are present? Anticoagulation alone may be sufficient in patients presenting with clearly focal vascular events. Should psychotropics be administered to lupus patients with predominantly psychiatric presentations? It is in the latter group of patients, particularly those who are on high-dose steroid therapy and who may present with a psychotic state, that most diagnostic and therapeutic dilemmas occur. Does the patient suffer from a primary psychiatric disorder, for example, manic depressive psychosis/ schizophrenia, or is the condition solely lupus induced, and to what extent are the steroids contributing to the psychotic state? Some of these difficulties and some current concepts relating to NP-SLE will be addressed in this review article.
Pathology
The first study of pathology in patients with lupus presenting with neurological symptoms and signs was that by Kaposi in 1872.20 He reported on patients with headache, delirium and coma and noted a variety ofabnormalities, including cerebral atrophy and thickened, inflamed meninges. Subsequently, however, neurological abnormalities were most often attributed to cerebral vasculitis, to Semliki Forest virus (SFV) and to galactocerebrosides (GALC) in SLE patients as well as in patients with the 'primary' anti-phospholipid syndrome; the authors hypothesized that the antibody reactivity to SFV, particularly in the SLE anticardiolipin-positive patients appeared to be more specific than the reaction of antibodies to native GALC, and might represent reactivity to an undetermined glycophospholipid present in the envelope of some viruses such as SFV. 56 Recently, several potential lymphocyte/brain antigens have been studied by immunoprecipita- The most recent autoantibody candidates invoked in the causation of NP-SLE are the antibodies directed to anti-ribosomal P, mostly seen in association with psychosis and depression.65 67One patient with recurrent psychotic episodes studied recently was, however, negative for these antibodies in a prospective study.67 However, a second more recent case study tended to confirm the original observations.68 Since abnormalities of both cytokine and antibody production occur with lupus, future studies of the mechanisms of brain dysfunction should include both a study of cytokines as well as antibodies in the sera and cerebrospinal fluid of lupus patients.
Cognitive impairment
A number of factors have been postulated as being involved in the production ofcognitive impairment in SLE. These include: (1) the use of corticosteroids; (2) the non-specific effects of disease activity; and (3) psychological distress. Some of these will be briefly reviewed.
Steroids
Since high doses of corticosteroids have been reported as being associated with psychosis77 it is certainly plausible that corticosteroid therapy could, to some extent, contribute to cognitive impairment found in SLE patients. However, most investigators have found no significant association between cognitive impairment and either steroid therapy at the time of test78-82 or steroid dosage.78 '83 In fact it seems possible that steroid therapy may actually improve memory or other cognitive functions in SLE. Each of ten patients participating in single patient (N = 1) corticosteroid trials showed better performances after the first three week exposure to drug than to placebo,84 and Ginsburg et al.8' reported an association between steroid use and improved performance on complex attention tasks in their older SLE patients. Taken together, these findings strongly suggest that the higher prevalence of cognitive impairment in lupus patients cannot be attributed to corticosteroid treatment. A similar conclusion has in fact been reached with respect to the possible effect of corticosteroids on the memory impairment documented in patients with multiple sclerosis. 85 
Chronic disease
Similarly, the contribution of chronic disease and/ or constitutional symptoms to cognitive impairment has been evaluated. There was no significant association between cognitive impairment and scores on either the LACC (Lupus Activity Criteria Count),78'79 an index of lupus activity which tallies the number of active organ systems,86 the SLEDAI83 and SLAM81 scales, or other newer indices of disease activity.87 It is worthwhile noting that a lack of association between the degree of physical disability and significant cognitive function, particularly memory impairment, has also been reported in studies on patients with multiple sclerosis.88 '89 There have also been very few significant associations found between individual organ system involvement in SLE and cognitive impairment; in particular, patients with renal involvement, which may be associated with CNS complications, were not more likely to show significant cognitive impairment than those with skin and joint involvement.9 It is thus unlikely that the high prevalence of significant cognitive impairment in SLE patients is simply a reflection of systemic illness.
Psychological distress
Lastly, although SLE patients experience and report considerable psychological distress, irrespective ofwhether their NP symptoms are active or inactive,91'92 there is no significant association between the presence of emotional distress and cognitive impairment.78 This is consistent with a recent report of symptoms of anxiety and depression in ambulatory SLE patients independent of cognitive defects.93 It would therefore appear that significant emotional distress is unlikely by itself to result in significant cognitive impairment in SLE, and, conversely, that emotional distress is not a necessary response to cognitive dysfunction. The two, however, may certainly co-occur. 78 There is considerable diversity in the kinds of cognitive impairment shown by SLE patients, although memory problems are very common. Cognitive impairment has been found in up to one-half of SLE patients using quantitative criteria alone, reaching two-thirds if qualitative criteria (that is, test taking behaviours) are also considered. 78 A recent prospective study of the neuropsychiatric manifestations of SLE attempted to differentiate between primary involvement by the lupus process and secondary causes.'06 Included in the primary group were psychoses, seizures, multiple cerebral infarction, papillitis, neuropathy and myelopathy. The commonest causes in the secondary group were infections, the administration of steroids, or encephalopathy associated with hypertension. These secondary patients manifested confusional states, seizures, headaches as well as psychosis (steroids). Infections included chronic bacterial (tuberculosis), fungal (aspergillus, cryptococcus, micormycosis, nocardia, or candida), acute bacterial (staphylococcus), klebsiella or viral (hepatitis, cytomegalovirus). These are most likely to result in major behavioural changes (suicide attempts, disorientation, major depression, confusion, hallucinations, states of altered alertness). These same manifestations were also noted in the series recently documented by Futrell et al.27 who noted that these manifestations were often accompanied by contributing factors such as infections and/or azotaemia. The presence of systemic infection seem to occur most frequently in patients with decreased states of alertness. Steroids were only really implicated as a factor and were considered as a cause of psychosis in two patients in the previous study. "" Psychosis developed within 7 days after the commencement of prednisone (60 mg and 30 mg, respectively) in both patients. Both had active disease during the episodes of psychotic behaviour. The prednisone was reduced to 5 mg daily and oral azathioprine and cyclophosphamide were given as steroid-sparing agents. The patients recovered without any neurological deficits.
There may on occasion be difficulties resulting from the differentiation of a primary lupus psychosis from steroid-induced states. Steroid psychosis in SLE patients is rare and appears in less than 5% of SLE patients.'07 Several studies of steroid-induced psychiatric syndromes have shown that the predominant psychiatric manifestations appear to be changes in mood or affect (depression or mania), while frank psychosis is rare (13% of cases only).108," The majority of patients, as in the two cases quoted above, developed their symptoms within 2 weeks of the commencement of steroid treatment and in most (77%) the changes developed on doses greater than 40 mg. The mental changes resolved after between 2 and 60 days (with a mean of 24 days) following tapering of steroid dosage. In contrast to steroid-induced psychiatric syndromes, SLE patients have a high incidence of psychosis (24%), the majority (61%) of neuropsychiatric manifestations occur within the first year after the initial diagnosis of SLE and their frequency tends to decrease with time, but usually lasts longer than the steroid-induced psychotic conditions. "O In summary therefore, NP-SLE still remains a complex clinical situation with no single pathogenetic cause. The estimation of autoantibodies particularly those directed against cardiolipin, ribosomal-P and certain shared lymphocyte/brain antigens might assist in defining 'subsets'. Therapy still is individually 'tailored', although guiding principles enumerated in this article may certainly be of assistance in a particular case. 
